The National Pharmaceutical Pricing Authority (NPPA) has allowed Abbott Healthcare to discontinue its drug-eluting stent, Alpine, from the Indian market - a decision that is sending mixed signals to the market. The NPPA has already permitted Abbott to withdraw its dissolvable stent, Absorb, from the market. NPPA's move has raised concerns over a 'sudden shortage' of cardiac stents in the market. NPPA has brought cardiac stents under price control and reduced the price of a drug-coated stent to Rs30,000 from Rs1.5- 1.9 lakh earlier. However, companies like Abbott and Medtronic have decided to withdraw some of their top drug-eluting stents from the Indian market as their margins would get hit.
Copyright (c) 2017 . Informatics India Ltd., source Indian Business Insight